Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold 1,343 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- Richard William Scalzo, a senior executive at Dyne Therapeutics, sold 1,343 shares of the company's common stock on March 11, 2025.
- The sale was executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted to Scalzo in December 2021 and December 2022.
- The shares were sold at a weighted average price of $11.38, with individual transactions ranging from $11.25 to $11.48.
- Following the transaction, Scalzo directly owns 122,330 shares of Dyne Therapeutics, which includes 109,054 unvested RSUs.
- The sale was conducted under a pre-arranged plan (Rule 10b5-1) to cover tax liabilities, not as a discretionary trade.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations and doesn't indicate a change in the executive's confidence in the company.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was not based on insider information or a discretionary decision to sell.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units (RSUs) that vest over time.
- Upon vesting, these RSUs are subject to income tax, and executives often sell a portion of the shares to cover these tax obligations.
- The use of Rule 10b5-1 plans is a standard practice to avoid accusations of insider trading, as these plans are established in advance and specify the timing and amount of trades.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small percentage of the total outstanding shares and is a routine transaction.
Key Dates
| Date | Description |
|---|---|
| December 10, 2021 | Date of restricted stock unit grant to the Reporting Person. |
| December 9, 2022 | Date of restricted stock unit grant to the Reporting Person. |
| 03/11/2025 | Date of stock sale transaction. |
| 03/13/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.